Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Canopy GrowthCGC -3.68%40 Days Sales Outstanding is 36.26 as of Jun. 2026, which is 30% below its 10-year median of 51.81. GuruFocus rates CGC with a GF Score™ of 40/100 and a GF Value™ of $0.71 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 947 Drug Manufacturers companies, Canopy Growth ranks better than 82.15% on this metric.
Canopy Growth's average Accounts Receivable for the
three
months ended in Jun. 2026 was $23.0 Mil. Canopy Growth's Revenue for the
three
months ended in Jun. 2026 was $57.8 Mil.
Hence, Canopy Growth's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 36.26.
The historical rank and industry rank for Canopy Growth's Days Sales Outstanding or its related term are showing as below:
CGC'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 17.86 Med: 51.81 Max: 67.41
Current: 41.1
During the past 13 years, Canopy Growth's highest Days Sales Outstanding was 67.41. The lowest was 17.86. And the median was 51.81.
CGC's Days Sales Outstanding is ranked better than 82.15% of 947
companies
in the Drug Manufacturers industry
Industry Median: 71.92
vs CGC: 41.10
Canopy Growth's Days Sales Outstanding
declined
from Jun. 2025 (58.95) to Jun. 2026 (36.26).
Canopy Growth (NAS:CGC) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Canopy Growth Days Sales Outstanding Related Terms
Canopy Growth Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Canopy Growth's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Canopy Growth's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Canopy Growth Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Canopy Growth's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Canopy Growth's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Canopy Growth (CGC) has a Days Sales Outstanding of 36.26 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Canopy Growth and its competitors. This is 30% below median its historical median of 51.81. Over the past decade, Canopy Growth's Days Sales Outstanding has ranged from 17.86 to 67.41. According to the industry distribution chart, Canopy Growth ranks #169 out of 947 companies in the Drug Manufacturers industry, placing it in the top 17.8%.
Is Canopy Growth's Days Sales Outstanding too high?
Canopy Growth's current Days Sales Outstanding of 36.26 is 30% below median its 10-year median of 51.81. Over the past 10 years, this metric has ranged from a low of 17.86 to a high of 67.41. The Drug Manufacturers industry median Days Sales Outstanding is 71.92. Canopy Growth's value of 36.26 is 49.6% below this industry median. Based on the distribution chart, Canopy Growth ranks #169 out of 947 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Canopy Growth has a GF Score™ of 40/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Canopy Growth's Days Sales Outstanding compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Canopy Growth ranks #169 out of 947 companies for Days Sales Outstanding. This places Canopy Growth in the top 18% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 71.92. Canopy Growth's value of 36.26 is 49.6% below this benchmark. Historically, Canopy Growth's own Days Sales Outstanding has ranged from 17.86 to 67.41 over the past decade. While the company's 10-year median is 51.81 vs. the industry median of 71.92, Canopy Growth has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 71.92, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Canopy Growth's current Days Sales Outstanding of 36.26 is 49.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Canopy Growth and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 71.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Canopy Growth's current Days Sales Outstanding is 36.26, which is 30% below median its own 10-year median of 51.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Canopy Growth stock overvalued right now?
Based on GuruFocus' analysis, Canopy Growth (CGC) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.71, compared to a current price of $0.93 — trading 31% above its estimated fair value. The current Days Sales Outstanding is 36.26, which is 30% below median its 10-year median of 51.81 and 49.6% below the Drug Manufacturers industry median of 71.92. Canopy Growth's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Canopy Growth (CGC), the current Days Sales Outstanding is 36.26 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Canopy Growth (CGC) Overvalued in 2026?
Based on GuruFocus' analysis, Canopy Growth stock appears to be overvalued.
The current stock price of $0.93 is trading 31% above its estimated GF Value™ of $0.71.
GuruFocus considers Canopy Growth to be Modestly Overvalued.
Key valuation signals for CGC:
Days Sales Outstanding: 36.26 (30% below median its 10-year median of 51.81)
GF Value™: $0.71 vs. price of $0.93 (31% above fair value)
Industry Position: 49.6% below the Drug Manufacturers median (#169 of 947)
No single metric tells the full story. See the CGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.
40GF Score
Get the complete analysis for CGC
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CGC has been successfully added to your 
